logo-loader
RNS
Physiomics PLC

Result of AGM, Issue of Equity & TVR

RNS Number : 0146C
Physiomics PLC
05 November 2026
 

Physiomics | Physiomics - Model Informed Drug Development - Pharmacometrics, Quantitative System Pharmacology and Biostatistics Consulting
5 November 2026

 

Physiomics plc

("Physiomics" or the "Company")

 

Result of AGM

Issue of Equity, TVR, and Directors' Dealing

 

The Annual General Meeting of Physiomics was held today at 10.30 a.m. (GMT) at Strand Hanson, 26 Mount Row, Mayfair, London, W1K 3SQ. The Company is pleased to confirm that all resolutions put to shareholders were duly passed.

 

Full details of the poll results are set out below:

 

Resolution

For

Against

Discretion to Chairman

Withheld

Total

01

34,189,515

334,719

Nil

2,383

34,526,617

02

31,959,123

386,078

Nil

2,181,416

34,526,617

03

33,335,879

334,719

Nil

856,019

34,526,617

04

33,335,879

334,719

Nil

856,019

34,526,617

05

33,335,879

334,719

Nil

856,019

34,526,617

06

33,327,858

334,719

Nil

864,040

34,526,617

07

33,328,453

334,719

Nil

863,445

34,526,617

08

34,140,207

384,027

Nil

2,383

34,526,617

09

33,335,879

334,719

Nil

856,019

34,526,617

10

32,019,098

334,719

Nil

2,172,800

34,526,617

 

The number of shares in issue at 6:30 p.m. (UK) on 4 November 2026 was 453,208,718. The Company does not hold any shares in treasury.

 

Issue of Equity

As announced on 30 June 2026, the board of directors of Physiomics (the "Board" or the "Directors") agreed to receive new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in lieu of part of their cash remuneration.  Following the AGM, Nick Tulloch, Chairman, will be issued 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will be issued 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board.  

 

Admission and Total Voting Rights

 

Application has been made for 14,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 8:00 a.m. on 11 November 2026. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares.

 

Following Admission, the Company's enlarged share capital will comprise 467,208,718 Ordinary Shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 467,208,718. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

ENDS

 

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

 

Enquiries:

Physiomics plc

Mike Whitlow

 

Email:  info@physiomics.co.uk

Strand Hanson Ltd (NOMAD and Broker)

James Dance & James Bellman

Tel:  +44 (0) 20 7409 3494

 

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Nick Tulloch

Non-Executive Chairman

Mike Whitlow

Executive Director

Ian Bagnall

Finance Director and Company Secretary

2. 

Reason for the Notification

a)

Position/status

See 1a) above

b)

Initial notification/Amendment

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics Plc

b)

LEI

213800A71DSZ6ABMTQ91

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 0.4p each in Physiomics Plc

 

Identification code

ISIN: GB00BDR6W943

b)

Nature of the transaction

Remuneration Shares

 

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Nick Tulloch

£0.005

4,000,000

Mike Whitlow

£0.005

5,000,000

Ian Bagnall

£0.005

5,000,000

d)

Aggregated information:



-  Aggregated volume

14,000,000


-  Price

£0.005

e)

Date of the transaction

5 November 2026

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBABTTMTMMBBF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read